Previous Close | 0.1960 |
Open | 0.1951 |
Bid | 0.1997 x 900 |
Ask | 0.1998 x 800 |
Day's Range | 0.1920 - 0.1998 |
52 Week Range | 0.1340 - 1.3100 |
Volume | |
Avg. Volume | 1,220,683 |
Market Cap | 8.357M |
Beta (5Y Monthly) | 2.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8900 |
Earnings Date | Nov 09, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AMTI
Looking at Applied Molecular Transport Inc.'s ( NASDAQ:AMTI ) insider transactions over the last year, we can see that...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined
GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif., September 21, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) ("AMT"), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant